Literature DB >> 11163355

C3A binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8.

T Monsinjon1, P Gasque, A Ischenko, M Fontaine.   

Abstract

The complement (C) plays an important role in many acute inflammatory processes. C3a is an inflammatory polypeptide named anaphylatoxin, generated during C activation and which acts through a specific receptor C3aR. In this study, we demonstrated that the epithelial cell line ECV 304 constitutively expressed C3aR (by flow cytometry and immunofluorescence) and that binding of purified C3a to epithelial cells resulted in a time- and dose-dependent upregulation of interleukin-8 (IL-8). Pre-treatment of ECV 304 with pertussis toxin inhibited IL-8 response induced by C3a, indicating that the action of C3a was mediated by a G protein coupled pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163355     DOI: 10.1016/s0014-5793(00)02320-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Differential gene expression in the periprosthetic membrane: lubricin as a new possible pathogenetic factor in prosthesis loosening.

Authors:  Lars Morawietz; Thorsten Gehrke; Lars Frommelt; Petra Gratze; Andreas Bosio; Johannes Möller; Bernhard Gerstmayer; Veit Krenn
Journal:  Virchows Arch       Date:  2003-05-29       Impact factor: 4.064

2.  Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge.

Authors:  Irene Bosch; Kris Xhaja; Luis Estevez; Gregory Raines; Heather Melichar; Rajas V Warke; Marcia V Fournier; Francis A Ennis; Alan L Rothman
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Authors:  Hongmei Gu; Amanda J Fisher; Elizabeth A Mickler; Frank Duerson; Oscar W Cummings; Marc Peters-Golden; Homer L Twigg; Trent M Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2016-03-08       Impact factor: 5.191

Review 4.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

5.  Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats.

Authors:  B P Morgan; M Griffiths; H Khanom; S M Taylor; J W Neal
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

6.  Interleukin-1beta and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes.

Authors:  Anne-christine Jauneau; Alexander Ischenko; Alexandra Chatagner; Magalie Benard; Philippe Chan; Marie-therese Schouft; Christine Patte; Hubert Vaudry; Marc Fontaine
Journal:  J Neuroinflammation       Date:  2006-04-04       Impact factor: 8.322

7.  Protective effects of decay-accelerating factor on blast-induced neurotrauma in rats.

Authors:  Yansong Li; Mikulas Chavko; Jessica L Slack; Bin Liu; Richard M McCarron; James D Ross; Jurandir J Dalle Lucca
Journal:  Acta Neuropathol Commun       Date:  2013-08-16       Impact factor: 7.801

8.  Negative regulation of pulmonary Th17 responses by C3a anaphylatoxin during allergic inflammation in mice.

Authors:  Hoyong Lim; Young Uk Kim; Scott M Drouin; Stacey Mueller-Ortiz; Kyoungah Yun; Eva Morschl; Rick A Wetsel; Yeonseok Chung
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration.

Authors:  Tracy Haynes; Agustin Luz-Madrigal; Edimara S Reis; Nancy P Echeverri Ruiz; Erika Grajales-Esquivel; Apostolia Tzekou; Panagiotis A Tsonis; John D Lambris; Katia Del Rio-Tsonis
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 10.  The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy.

Authors:  James E Pease; Ian Sabroe
Journal:  Am J Respir Med       Date:  2002
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.